Valganciclovir (Valcyte) coverage
Defines medical necessity criteria, authorization requirements, and approval durations for valganciclovir (Valcyte) for transplant prophylaxis, CMV retinitis, CMV-associated GI disease, post-transplant CMV infection, and other indications for members under Health Net (Centene) lines of business.
Added off-label coverage for treatment of post-transplant CMV infection as supported by practice guidelines.
Added requirement in both initial and continuation requests that member must use generic valganciclovir for the formulation being requested unless contraindicated.
For off-label post-transplant CMV infection, Valcyte must not be prescribed concurrently with Livtencity.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.